Integrated Filing — IndAS



General information about company

Scrip Code 500120
NSE Symbol DIAMINESQ
MSEI Symbol NOTLISTED
ISIN INE591D01014
Name of company DIAMINES & CHEMICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 12-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 03-02-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Third quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 12-02-2026   11:30:00
End date and time of board meeting 12-02-2026   12:35:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
NOT APPLICABLE



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 763.87 2,917.05
Other income 71.76 354.57
Total income 835.63 3,271.62
2 Expenses
(a) Cost of materials consumed 210.66 1,700.03
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 191.26 (199.94)
(d) Employee benefit expense 272.95 805.01
(e) Finance costs 13.36 21.19
(f) Depreciation, depletion and amortisation expense 89.30 257.82
(f) Other Expenses
1 Other Expenses 361.66 1,646.18
Total other expenses 361.66 1,646.18
Total expenses 1,139.19 4,230.29
3 Total profit before exceptional items and tax (303.56) (958.67)
4 Exceptional items 0.00 0.00
5 Total profit before tax (303.56) (958.67)
6 Tax expense
7 Current tax (18.84) 0.00
8 Deferred tax 7.83 (56.70)
9 Total tax expenses (11.01) (56.70)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (292.55) (901.97)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (292.55) (901.97)
17 Other comprehensive income net of taxes 15.71 35.82
18 Total Comprehensive Income for the period (276.84) (866.15)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 978.40 978.40
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -2.99 -9.22
Diluted earnings (loss) per share from continuing operations -2.99 -9.21
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -2.99 -9.22
Diluted earnings (loss) per share from continuing and discontinued operations -2.99 -9.21
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-12-2025 31-12-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Speciality Chemicals 0.0076387 2,917.05
2 Trading in Fruits & Vegetables 0.00 0.00
Total Segment Revenue 763.87 2,917.05
Less: Inter segment revenue 0.00 0.00
Revenue from operations 763.87 2,917.05
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Speciality Chemicals (290.20) (937.48)
2 Trading in Fruits & Vegetables 0.00 0.00
Total Profit before tax (290.20) (937.48)
i. Finance cost 13.36 21.19
ii. Other Unallocable Expenditure net off Unallocable income 0.00 0.00
Profit before tax (303.56) (958.67)
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Speciality Chemicals 16,986.06 16,986.06
2 Trading in Fruits & Vegetables 0.00 0.00
Total Segment Asset 16,986.06 16,986.06
Un-allocable Assets 0.00 0.00
Net Segment Asset 16,986.06 16,986.06
4 Segment Liabilities
Segment Liabilities
1 Speciality Chemicals 1,311.83 1,311.83
2 Trading in Fruits & Vegetables 0.00 0.00
Total Segment Liabilities 1,311.83 1,311.83
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 1,311.83 1,311.83
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Gain/(Loss) on measuring equity instruments at Fair Value carried through Other Comprehensive Income (FVTOCI) 11.39 44.75
2 Remeasurement gain/(loss) on the Defined Benefit Plans 7.95 (3.38)
Total Amount of items that will not be reclassified to profit and loss 19.34 41.37
2 Income tax relating to items that will not be reclassified to profit or loss 3.63 5.55
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 15.71 35.82





Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 01-10-2024
Amount Raised 5,058.47
Report filed for Quarter ended 31-12-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review None
Comments of the auditors, if any NA
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Capital expenditures, working capital requirements, acquisition, investment in technology and for general corporate purpose NA 5,058.47 0.00 1,250.82 0.00 1250.82 lakhs received up to 26.09.2024 (i.e. 25% of the issue) and total funds were utilised for the quarter ended on December 31, 2025. Note: The Company had received In-principle approval for issue not exceeding 916390 number of convertible warrants at Rs. 552 per warrant. The Company had allotted 906390 convertible warrants on receipt of subscription money Rs. 1250.82 lakhs i.e. 25% of the total Issue, on preferential basis to the investors on 01.10.2024 and total funds were utilised for the quarter ended on December 31, 2025.Total issue will be of 5003.27 lakhs.


Signatory Details

Name of signatory Hemaxi Pawar
Designation of person Company Secretary
Place Vadodara
Date 12-02-2026